Straits Research Logo- p.jpg
Global Insulin Glargine Market Size is projected to reach USD 2200 million by 2031, growing at a CAGR of 6.11%: Straits Research New York, United States, March 20, 2024 (GLOBE NEWSWIRE) -- Insulin glargine is a modified, long-acting form of medical insulin used to treat diabetes types I and II. It is subcutaneously injected....
logo 600X600.png
Feeding Tubes Market Size to Surpass Around US$ 9.69 Billion 2030, Recording a CAGR of 6.2% | Report by CoherentMI
March 20, 2024 06:21 ET | CMI
Burlingame, March 20, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, Feeding Tubes Market was valued at US$ 6.34 Billion in the year 2023 and is anticipated to reach US$ 9.69...
Sequel twiist(TM) Automated Insulin Delivery (AID) system
Sequel’s twiist™ Automated Insulin Delivery System Receives FDA 510(k) Clearance
March 18, 2024 07:05 ET | Sequel Med Tech
Sequel’s twiist™ automated insulin delivery system receives FDA 510(k) clearance. Significant advancements for people with people with Type 1 diabetes.
Research Nester Logo.jpg
Drug Delivery Systems Market revenue to exceed USD 433 Billion by 2035, says Research Nester
March 18, 2024 05:00 ET | Research Nester
New York, March 18, 2024 (GLOBE NEWSWIRE) -- The global drug delivery systems market size is slated to expand at ~11% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 433...
cmi_logo.png
[Latest] Global mHealth Market Size/Share Worth USD 374.6 Billion by 2032 at a 17.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
March 14, 2024 12:30 ET | Custom Market Insights
Austin, TX, USA, March 14, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “mHealth Market Size, Trends and Insights By Device Type (Cardiac Monitors,...
download (1).png
Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes
March 14, 2024 04:14 ET | Atrogi
SOLNA, Sweden, March 14, 2024 (GLOBE NEWSWIRE) -- Atrogi, a pioneering clinical-stage biotech company advancing treatments for metabolic disorders, announces the full set of results from its Phase 1...
Research Nester Logo.jpg
Chronic Disease Management Market revenue to reach USD 27 Billion by 2035, says Research Nester
March 13, 2024 07:30 ET | Research Nester
New York, March 13, 2024 (GLOBE NEWSWIRE) -- The global chronic disease management market size is projected to grow at a CAGR of over ~13% from 2023 to 2035. The market is expected to garner a...
Fractyl-Logo.png
UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
March 12, 2024 14:06 ET | Fractyl Health, Inc.
Fractyl Health today announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform.
Fractyl-Logo.png
Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
March 12, 2024 08:38 ET | Fractyl Health, Inc.
Fractyl Health today announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform.
Arecor logo.jpg
ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY
March 12, 2024 07:30 ET | Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY Companies to combine proprietary...